about
A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKDCefotetan pharmacokinetics in volunteers with various degrees of renal function.Drug therapy in patients with chronic renal failure.Glomerular filtration rate and creatinine clearance.Didanosine pharmacokinetics in patients with normal and impaired renal function: influence of hemodialysis.Pharmacokinetics of cefotiam and cefsulodin after simultaneous administration to patients with impaired renal function.Pharmacokinetics of carumonam in patients with renal insufficiency.Cefoxitin pharmacokinetics: relation to three different renal clearance studies in patients with various degrees of renal insufficiency.Development of a computerised decisions support system for renal risk drugs targeting primary healthcareUnderstanding usage patterns of handheld computers in clinical practice.Drug dosing in patients with impaired renal function.Impact of renal aging on drug therapy.Disease states and drug pharmacokinetics.Does Secretory Clearance Follow Glomerular Filtration Rate in Chronic Kidney Diseases? Reconsidering the Intact Nephron Hypothesis.Protein binding and kinetics of drugs in liver diseases.Organic anion transporter OAT1 is involved in renal handling of citrulline.Metabolism and pharmacokinetics of the antibiotic rifampin.Suboptimal antimicrobial drug exposure in patients with renal impairment.Prediction of the renal clearance of cimetidine using endogenous N-1-methylnicotinamide.[Antibiotic dosing for renal function disorders and continuous renal replacement therapy].Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs.Cancer and the kidney: dangereoux liasons or price paid for the progress in medicine?Pharmacokinetic characterization of baclofen in patients with chronic kidney disease: dose adjustment recommendations.Pharmacokinetics of dexrazoxane in subjects with impaired kidney function.A pharmacokinetic model-independent approach for estimating dose required to give desired steady-state trough concentrations of drug in plasma.Predictive performance of four pharmacokinetic methods for calculating digoxin dosage.
P2860
Q28087621-7BBBC4B7-6F80-4872-9B4D-F1B2BE789C1DQ33739458-1BBDC08F-F1B7-446B-94D3-E325BE46A390Q34206012-75AA58F3-0C25-436B-81FB-8585363770CCQ34448915-4992CB94-124E-42BD-8B8B-1EA0BD926677Q34547322-8EA571E0-6793-4C38-B005-D362FC612C95Q35568382-5F22AF31-6633-4142-B6C5-23CCE6358BC3Q35648524-101BEEBF-1510-4014-B18E-4A9519726DE9Q35672574-7656BD36-D9EC-4F7E-8012-AC7AE92487ECQ35844071-08C578C2-80CF-4D7A-8CB7-0C4DDD52F4C8Q36461707-17852A9D-6ED7-4CCD-B981-432C50C9C570Q37559261-8EA95530-03A5-4081-BA06-942C13C6D81FQ38544072-8F1FBED5-274B-4662-B0D1-8AF09C391AC8Q38689435-D4EF3B16-EEB8-4BD5-A235-40A1CECCA474Q38694525-9BA7EC6B-0A01-4303-AF6C-222EA536318CQ39620831-EAE89BA4-9653-488A-AF6A-096227923E6DQ39858796-85961472-7547-4BAB-9E7D-79776A4F98C7Q40317983-264574F6-BD51-4275-9AF9-0FF953B5F993Q40897031-CC65B5D1-832C-43BB-B524-F60740A5AF31Q41152114-4D2270FF-F88F-4C51-A62D-69E547CF7E2DQ41379961-1B3AAD8F-274D-444D-8208-FEEC13D2CF68Q42199670-7C25E22F-D46F-417A-B46A-D15D243DCFAFQ42371674-71F30A0E-EAD7-4080-8487-1A7098B237F7Q42637276-5C90E59A-6DF2-4458-B9C2-7E427D1FCE75Q51564910-3F378957-28C1-4099-A71E-D21347839A14Q52765659-3436B1B0-4CFB-43C3-AEA5-7FEF58A1AEAEQ52887073-4D5E9194-C277-45E1-8016-0269BF2ED686
P2860
description
1976 nî lūn-bûn
@nan
1976年の論文
@ja
1976年論文
@yue
1976年論文
@zh-hant
1976年論文
@zh-hk
1976年論文
@zh-mo
1976年論文
@zh-tw
1976年论文
@wuu
1976年论文
@zh
1976年论文
@zh-cn
name
Drug dosage in renal disease.
@en
type
label
Drug dosage in renal disease.
@en
prefLabel
Drug dosage in renal disease.
@en
P1476
Drug dosage in renal disease.
@en
P2093
P304
P356
10.2165/00003088-197601020-00004
P577
1976-01-01T00:00:00Z
P6179
1004939721